Novel Molecular Processes Controlling Key Genes in Prostate Cancer Uncovered
Researchers have elucidated gene regulatory mechanisms that can explain how known genetic variants influence prostate cancer risk. The findings reveal widespread deregulation of androgen receptor function, a key player in prostate cancer. [Press release from Karolinska Institutet discussing online prepublication in Nature Genetics] Press Release|Abstract
The Androgen Receptor Regulates PPARγ Expression and Activity in Human Prostate Cancer Cells
Investigators examined whether the androgen receptor (AR) regulates peroxisome proliferator activated receptor gamma (PPARγ) expression and function within human prostate cancer cells. qRT-PCR and Western blot analyses revealed nanomolar concentrations of the AR agonist dihydrotestosterone decrease PPARγ mRNA and protein within the castration-resistant, AR-positive C4-2 and VCaP human prostate cancer cell lines. [J Cell Physiol] Abstract
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-Resistant Prostate Cancer
The authors evaluated TMPRSS2-ERG expression using quantitative reverse transcription polymerase chain reaction in peripheral blood mononuclear cells and tumor tissue from metastatic resistant prostate cancer patients treated with taxanes. They examined peripheral blood mononuclear cells from 24 healthy controls, 50 patients treated with docetaxel, and 22 with cabazitaxel. [Eur Urol] Abstract
REVIEWS
Enhancing Active Surveillance of Prostate Cancer: The Potential of Exercise Medicine
Preliminary evidence suggests that lifestyle and/or exercise interventions might have therapeutic potential in this growing population of men with prostate cancer. However, several important issues remain unclear: the exact value of different types of lifestyle and exercise medicine interventions during active surveillance; the biological mechanisms of exercise in delaying disease progression; and the influence of the anxieties and distress created by having a diagnosis of cancer without then receiving active treatment. [Nat Rev Urol] Abstract
Active Surveillance for Prostate Cancer: Current Evidence and Contemporary State of Practice
Active surveillance (AS) has emerged as a primary management strategy in men with favourable-risk disease, and contemporary data suggest that use of AS has increased worldwide. Although published surveillance cohorts differ by protocol, reported rates of metastatic disease and prostate-cancer-specific mortality are exceedingly low in the intermediate term. [Nat Rev Urol] Abstract
Visit our reviews page to see a complete list of reviews in the prostate cell research field.
INDUSTRY NEWS
NeoTract, Inc. Announces First Patients Enrolled in New Study to Expand UroLift® System Indication
NeoTract, Inc. announced that the first patients have been enrolled in the MedLift™ U.S. IDE trial. The study is designed to demonstrate safety and effectiveness of the UroLift® System for the treatment of patients with benign prostatic hyperplasia who have an obstructive median lobe, which is currently contraindicated in the United States. [NeoTract, Inc.] Press Release
Ipsen and PeptiMimesis Announce a Research Partnership in Oncology
Ipsen and PeptiMimesis announced the signature of a research partnership and a licensing option for the development and marketing of novel therapeutic peptides in oncology. The target receptor is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation. [Ipsen] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!
